Literature DB >> 6903449

Activation of the alternative pathway of complement by microcrystalline cholesterol.

P Hasselbacher, J L Hahn.   

Abstract

Microcrystalline cholesterol in either the anhydrous or monohydrate form was a potent activator of the alternative pathway of complement as measured by the electrophoretic conversion (crossed immunoelectrophoresis) of C3 and properdin factor B. Chelation with 0.01 M ethylene-diaminetetraacetate (EDTA) completely eliminated conversion, but 0.01 M ethyleneglycol tetraacetate (EGTA) had little or no effect. The magnitude of activation by cholesterol crystals was similar to that by zymosan, heat-aggregated IgG, or crystals of monosodium urate monohydrate. The microcrystalline forms of the acetate, linoleate, or oleate esters of cholesterol did not activate more complement than did saline controls. Cholestanol retained full C3 activating potency, but cholestane had none. Binding of IgG by cholesterol monohydrate is very small compared to that by sodium urate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6903449     DOI: 10.1016/0021-9150(80)90009-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein.

Authors:  Takayuki Fujita; Takayuki Fujioka; Tetsuo Murakami; Atsushi Satomura; Yoshinobu Fuke; Koichi Matsumoto
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

2.  Activation of the alternative complement pathway and generation of stimulating factors for granulocytes by glass fibers.

Authors:  M Governa; M Valentino; I Visona; I Marchiseppe; N Lo Martire
Journal:  Cell Biol Toxicol       Date:  1988-06       Impact factor: 6.691

3.  Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.

Authors:  M Accad; S J Smith; D L Newland; D A Sanan; L E King; M F Linton; S Fazio; R V Farese
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 4.  Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies.

Authors:  Alicia J Jenkins; Maria B Grant; Julia V Busik
Journal:  Diabetologia       Date:  2022-02-11       Impact factor: 10.460

5.  Antibodies to cholesterol.

Authors:  G M Swartz; M K Gentry; L M Amende; E J Blanchette-Mackie; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

6.  The benign long-term effect of cholesterol crystal synovial cysts.

Authors:  H Gur; M Ehrenfeld
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

7.  Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles.

Authors:  M Doherty; J T Whicher; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

Review 8.  Macrophage Recognition of Crystals and Nanoparticles.

Authors:  Masafumi Nakayama
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

9.  Natural antibodies and CRP drive anaphylatoxin production by urate crystals.

Authors:  Anne Kathrin Wessig; Leonie Hoffmeister; Annika Klingberg; Anika Alberts; Andreas Pich; Korbinian Brand; Torsten Witte; Konstantin Neumann
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

Review 10.  Why AMD is a disease of ageing and not of development: mechanisms and insights.

Authors:  Kaushal Sharma; Neel Kamal Sharma; Akshay Anand
Journal:  Front Aging Neurosci       Date:  2014-07-10       Impact factor: 5.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.